Description: Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Home Page: www.anebulo.com
1017 Ranch Road 620 South
Lakeway,
TX
78734
United States
Phone:
512 598 0931
Officers
| Name | Title |
|---|---|
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
| Mr. Richard Anthony Cunningham | CEO & Director |
| Mr. Daniel V. George | Principal Accounting Officer, Acting CFO & Secretary |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 19.0842 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 2 |